Purpose: To evaluate the usefulness of serum lipoprotein(a) as a biomarker of clinical outcomes after endovascular therapy (EVT) for atherosclerotic aortoiliac lesions. Methods: Serum lipoprotein(a) concentrations were measured at admission in 189 consecutive patients (median age 72 years; 160 men) with peripheral artery disease who underwent EVT for aortoiliac occlusive disease. The patients were dichotomized into 2 groups based on serum lipoprotein(a) levels ≤40 mg/dL (LOW; n=135) or >40 mg/dL (HIGH; n=54). After EVT, the incidences of major adverse limb events (MALE) were analyzed. Predictors of MALE were sought with a Cox proportional hazards analysis; results are presented as the hazard ratio (HR) and 95% confidence interval. Results: At the median follow-up of 33 months (interquartile range 11, 54), MALE occurred in 44 (23.3%) patients. The MALE-free survival estimate was significantly lower in patients in the HIGH group (55.6% vs 85.2%, p<0.001). Independent predictors of MALE after EVT were hemodialysis (HR 2.23, 95% CI 1.04 to 4.78, p=0.039) and high lipoprotein(a) levels (HR 2.80, 95% CI 1.44 to 5.45, p=0.003). Conclusion: High lipoprotein(a) levels were associated with a higher incidence of MALE after EVT for patients with aortoiliac lesions.
2011 Writing Group Members, 2005 Writing Committee Members, ACCF/AHA Task Force Members. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, Circulation. 2011;124:2020–2045.
2.
OlinJWSealoveBA.Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc. 2010;85:678–692.
NorgrenLHiattWRDormandyJAet al; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–S67.
5.
HiattWR.Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001;344:1608–1621.
6.
KuglerCFRudofskyG.The challenges of treating peripheral arterial disease. Vasc Med. 2003;8:109–114.
7.
OlinJWWhiteCJArmstrongEJet al. Peripheral artery disease: evolving role of exercise, medical therapy, and endovascular options. J Am Coll Cardiol. 2016;67:1338–1357.
8.
RamosRGarcía-GilMComas-CufíMet al. Statins for prevention of cardiovascular events in a low-risk population with low ankle brachial index. J Am Coll Cardiol. 2016;67:630–640.
9.
GutierrezABhattDL.Medical management of peripheral artery disease in diabetes mellitus. Eur Heart J. 2015;36:1494–1495.
10.
BonacaMPCreagerMA.Pharmacological treatment and current management of peripheral artery disease. Circ Res. 2015;116:1579–1598.
DebACapliceM.Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol. 2004;27:258–264.
13.
KamstrupPRTybjaerg-HansenASteffensenRet al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–2339.
14.
WilleitPKiechlSKronenbergFet al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck study. J Am Coll Cardiol. 2014;64:851–860.
15.
GurdasaniDSjoukeBTsimikasSet al. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2012;32:3058–3065.
16.
KheraAVEverettBMCaulfieldMPet al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129:635–642.
17.
SeedMAyresKLHumphriesSEet al. Lipoprotein(a) as a predictor of myocardial infarction in middle aged men. Am J Med. 2001;110:22–27.
18.
RutherfordRBBakerJDErnstCet al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26:517–538.
19.
ConteMSGeraghtyPJBradburyAWet al. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg. 2009;50:1462–1473.
20.
RankeCCreutzigAAlexanderK.Duplex scanning of the peripheral arteries: correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol. 1992;18:433–440.
21.
GuoXLiJPangWet al. Sensitivity and specificity of ankle-brachial index for detecting angiographic stenosis of peripheral arteries. Circ J. 2008;72:605–610.
22.
IkenagaHIshiharaMInoueIet al. Usefulness of lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction. Circ J. 2011;75:2847–2852.
23.
NestelPJBarnesEHTonkinAMet al. Plasma lipoprotein(a) concentration predicts coronary and cardiovascular events in patients with stable coronary heart disease. Atheroscler Thromb Vasc Biol. 2013;33:2902–2908.
24.
Emerging Risk Factors Collaboration, ErqouSKaptogeSet al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality. JAMA. 2009;302:412–423.
25.
NaveAHLangeKSLeonardsCOet al. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis. 2015;242:496–503.
TsimikasSHallJL.Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012;60:716–721.
28.
ArgravesKMKozarskyKFFallonJTet al. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest. 1997;100:2170–2181.
29.
LiuACLawnRM.Lipoprotein(a) and atherogenesis. Trends Cardiovasc Med. 1994;4:40–44.
30.
MaherVMBrownBG.Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol. 1995;6:229–235.
31.
WuHDBerglundLDimayugaCet al. High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort. J Am Coll Cardiol. 2004;43:1828–1833.
32.
GraingerDJKirschenlohrHLMetcalfeJCet al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260:1655–1658.
33.
KostnerKMKostnerGM.Factors affecting plasma lipoprotein(a) levels: role of hormones and other nongenetic factors. Semin Vasc Med. 2004;4:211–214.
34.
ArmstrongVWSchleefJThieryJet al. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels. Eur J Clin Invest. 1989;19:235–240.
35.
BlomDJHalaTBologneseMet al; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809–1819.
